[1]
|
A. K. Wahi and A. Singh, “Triazole: Recent Development and Biological Activities,” Asian Journal of Biochemical and Pharmaceutical Research, Vol. 2, No. 1, 2011, pp. 193-205.
|
[2]
|
I. Pibiri and S. Buscemi, “A Recent Portrait of Bioactive Triazoles,” Current Bioactive Compounds, Vol. 6, No. 4, 2010, pp. 208-242. doi:10.2174/157340710793237281
|
[3]
|
J.-H. Chern and K.-S. Shia, “Design, Synthesis, and Structure-Activity Relationships of Pyrazolo[3,4-d]Pyrimidines: A Novel Class of Potent Enterovirus Inhibitors,” Bioorganic & Medicinal Chemistry Letters, Vol. 14, No. 10, 2004, pp. 2519-2525. doi:10.1016/j.bmcl.2004.02.092
|
[4]
|
H. A. Rotbart, “Treatment of Picornavirus Infections,” Antiviral Research, Vol. 53, No. 2, 2002, pp. 83-98.
doi:10.1016/S0166-3542(01)00206-6
|
[5]
|
V. A. Makarov, O. B. Riabova, et al., “Anti-Coxsackievirus B3 Activity of 2-AMINO-3-Nitropyrazolo[1,5-a]Pyrimidines and Their Ana-logs,” Bioorganic & Medicinal Chemistry Letters, Vol. 15, No. 1, 2005, pp. 37-39.
doi:10.1016/j.bmcl.2004.10.043
|
[6]
|
G. Pürstinger, “Synthesis and Anti-CVB 3 Evaluation of Substituted 5-Nitro-2-Phenoxybenzonitriles,” Bioorganic & Medicinal Chemistry Letters, Vol. 18, No. 18, 2008, pp. 5123-5125. doi:10.1016/j.bmcl.2008.07.099
|
[7]
|
M. Esfandiarei and B. M. McManus, “Molecular Biology and Pathogenesis of Viral Myocarditis,” Annual Review of Pathology: Mechanisms of Disease, Vol. 3, 2008, pp. 127-155.
doi:10.1146/annurev.pathmechdis.3.121806.151534
|
[8]
|
N. M. Chapman and K. S. Kim, “Persistent Coxsackievirus Infection: Enterovirus Persistence in Chronic Myocarditis and Dilated Cardiomyopathy,” Current Topics in Microbiology and Immunology, Vol. 323, 2008, pp. 275292. doi:10.1007/978-3-540-75546-3_13
|
[9]
|
J. Cheng, J. Xie and X. Luo, “Synthesis and Antiviral Activity against Coxsackie Virus B3 of Some Novel Benzimidazole Derivatives,” Bioorganic & Medicinal Chemistry Letters, Vol. 15, No. 2, 2005, pp. 267-269.
doi:10.1016/j.bmcl.2004.10.087
|
[10]
|
F. Xue and X. Luo, “Inhibitory Properties of 2-Substituent1H-Benzimidazole-4-Carboxamide Derivatives against Enteroviruses,” Bioorganic & Medicinal Chemistry, Vol. 19, No. 8, 2011, pp. 2641-2649.
doi:10.1016/j.bmc.2011.03.007
|
[11]
|
D. R. Guda, T. J. Wang and H. M. Cho, “Trimethylsilyl Isothiocyanate (TMSNCS): An Efficient Reagent for the One-Pot Synthesis of Mercapto-1,2,4-Triazoles,” Tetrahedron Letters, Vol. 53, No. 39, 2012, pp. 5238-5242.
doi:10.1016/j.tetlet.2012.07.054
|
[12]
|
Y. Dürüst, “Synthesis of Some Novel 1,3,4and 1,2,4Thiadiazole Derivatives,” Phosphorus, Sulfur, and Silicon, Vol. 184, No. 11, 2009, pp. 2923-2935.
doi:10.1080/10426500802625453
|
[13]
|
Z. L. Xin and H. Y. Zhao, “Synthesis and Structure-Activity Relationships of Isoxazole Carboxamides as Growth Hormone Secretagogue Receptor Antagonists,” Bioorganic & Medicinal Chemistry Letters, Vol. 15, No. 4, 2005, pp. 1201-1204. doi:10.1016/j.bmcl.2004.11.075
|
[14]
|
J. H. Kalin and H. K. Zhang, “Chiral Mercaptoacetamides Display Enantioselective Inhibition of Histone Deacetylase 6 and Exhibit Neuroprotection in Cortical Neuron Models of Oxidative Stress,” Chem-MedChem, Vol. 7, No. 3, 2012, pp. 425-439.
|
[15]
|
L. J. Reed and H. Muench, “A Simple Method for Estimating Fifty Percent Endpoints,” American Journal of Hygiene, Vol. 27, No. 3, 1938, pp. 493-497.
|